GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » S Biomedics Co Ltd (XKRX:304360) » Definitions » Capex-to-Revenue

S Biomedics Co (XKRX:304360) Capex-to-Revenue : 0.10 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is S Biomedics Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

S Biomedics Co's Capital Expenditure for the three months ended in Mar. 2024 was ₩-271.38 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩2,606.56 Mil.

Hence, S Biomedics Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.10.


S Biomedics Co Capex-to-Revenue Historical Data

The historical data trend for S Biomedics Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

S Biomedics Co Capex-to-Revenue Chart

S Biomedics Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial 0.68 0.11 0.04 0.06 0.09

S Biomedics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.06 0.22 0.14 0.10

Competitive Comparison of S Biomedics Co's Capex-to-Revenue

For the Biotechnology subindustry, S Biomedics Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


S Biomedics Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, S Biomedics Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where S Biomedics Co's Capex-to-Revenue falls into.



S Biomedics Co Capex-to-Revenue Calculation

S Biomedics Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1108.205) / 12112.652
=0.09

S Biomedics Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-271.377) / 2606.555
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


S Biomedics Co  (XKRX:304360) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


S Biomedics Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of S Biomedics Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


S Biomedics Co (XKRX:304360) Business Description

Traded in Other Exchanges
N/A
Address
Seongsui-ro 26-gil, 4th Floor, Wooil Venture Town Building 28, Seongdong-gu, FedEx building, Seoul, KOR, 04797
S Biomedics Co Ltd researches and develops cell therapies for regenerative biomedicine. It owns two platform technologies: Functionally Enhanced Cell Spheroid and Targeted Embryonic Stem Cell Differentiation for developing cell therapy products that overcome the limitations of existing cell therapy products.

S Biomedics Co (XKRX:304360) Headlines

No Headlines